Short answer
Theravance Biopharma, Inc. (TBPH) filed an 8-K current report with the SEC on August 25, 2026 reporting Item 8.01 (Other Events). Presentation updates Phase 3 CYPRESS Study 0197 of ampreloxetine in symptomatic nOH associated with MSA.
Theravance Biopharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Presentation updates Phase 3 CYPRESS Study 0197 of ampreloxetine in symptomatic nOH associated with MSA
- Post hoc CYPRESS analyses may refine interpretation of ampreloxetine efficacy and safety data
- FDA interactions provide potential regulatory-development insight for the ampreloxetine program
- Exhibit 99.1 contains the substantive study and regulatory details; information furnished, not filed under Section 18
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Theravance Biopharma, Inc. 8-K filings
Get the next TBPH 8-K as it lands
Follow TBPH for push alerts, or ask the research agent what this filing means.